My Size Inc (MYSZ) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The setup is weak technically, there is no supportive news or fundamental momentum, and there are no bullish proprietary trading signals. Given the user wants a direct decision and is unwilling to wait for an optimal entry, the correct call is to avoid buying now and stay on the sidelines.
The technical picture is bearish. MACD histogram is negative at -0.0112 and still contracting, showing weak momentum. SMA structure is bearish with SMA_200 > SMA_20 > SMA_5, which confirms the broader trend remains down. RSI_6 at 23.818 suggests the stock is weak and near oversold conditions, but not yet a reliable reversal signal. Price is trading pre-market at 0.52, below the pivot level of 0.581 and near S1 at 0.531, with S2 at 0.501 as the next nearby downside area. The short-term candlestick pattern model implies a possible next-day bounce, but the broader trend remains unfavorable for a long-term entry.
There are no recent news catalysts, no positive hedge fund or insider accumulation, and no bullish AI Stock Picker or SwingMax signal. The only mild positive is the model-based near-term chance of a short bounce, but that is not strong enough to support a long-term buy decision.
No news in the last week, no valuation support, no financial snapshot available, hedge funds are neutral, insiders are neutral, and there is no recent congress trading data. Technically, the stock remains in a bearish trend with weak momentum and trading below key resistance. AI Stock Pick is absent and SwingMax has no recent signal.
Latest quarter financials were not available because the financial snapshot returned an error, so there is no usable evidence of recent revenue or earnings growth trends for the latest reported quarter season.
No analyst rating or price target changes were provided, so there is no visible Wall Street upgrade/downgrade trend to support a bullish view. Based on the available data, pros are effectively neutral-to-negative: no institutional buying, no insider support, and no catalyst-driven upside. Cons dominate: weak trend, no news, and no valuation/fundamental confirmation.
